A Study of TQB3820 in Patients With Hematological Malignancies
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor
in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and
subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1)
and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct
multiple aspects of the immune dysregulation mediated by B cells.